Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer
Swedish biotech firm Aqilion has acquired a phase-1 ready candidate from Leo Pharma, and the firm is aiming to address a high unmet medical need in the form of the inflammation disease, eosinophilic esophagitis. Through the deal, Leo Pharma also becomes a shareholder of Aqilion.
by albert rønning-andersson, translated by daniel pedersen
International attention continues to be fixed on Leo Pharma, which saw its CEO Catherine Mazzacco step down with immediate effect last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Headhunter calls outgoing Leo Pharma CEO a "flop"
For subscribers
CSL eyeing acquisition candidate in Vifor Pharma
For subscribers
.jpg&w=384&q=75)
